Navigation Links
China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Date:1/29/2008

OLDERS' EQUITY

Registered and paid up common stock 7,852,802 7,852,802

Accumulated other comprehensive income 368,681 152,162

Accumulated deficits (1,476,381) (2,167,267)

TOTAL STOCKHOLDERS' EQUITY 6,745,102 5,837,697

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $9,299,928 $7,277,752

Landway Bionanometer Technology Joint-stock Co., Ltd Co., Ltd

Statements of Cash Flows

(Stated in US Dollars)

Year ended December 31,

2006 2005

Cash flows from operating activities

Net income $690,886 $(80,824)

Adjustments to reconcile net income to

net cash provided by operating activities:

Depreciation 79,366 76,359

Provision for doubtful debts 89,030 76,341

Changes in operating assets and liabilities:

Trade receivables (709,433) (19,366)

Other receivables, prepayments and

deposits (32,942) 25,086

Amount due from related parties (333,643) (197,735)

Inventories 227,460 45,767

Deferred tax assets 350,705 (2,307)

Trade payables 10,651 31,507

Other payables and accrued expenses 860,018 619,704

Amount due to related parties 52,155 74,632

Receipt in advance (5,626) (73,339)

Net cash flows provided by operating

activitie
'/>"/>

SOURCE Xi'an Landway Bionanometer Technology Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
2. PPD Expands Global Central Lab Services into China
3. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
4. China Biologic Products Gains Financial Support from Shandong Provincial Government on the Improvement of Production Facilities
5. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
6. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
7. China Medical Technologies Completes Acquisition of BBE
8. Three Steps to Boost Asymchems Investment in China
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
10. AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China
11. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... FOSTER CITY, Calif. , April 20, 2015 /PRNewswire/ ... with InterpretOmics Pvt. Ltd. to provide an integrated Big ... analysis of all biomarkers collected in the context of ... the needs of precise or multi-targeted drug candidates, stratified ... efficacy and disease progression free survival. ...
(Date:4/20/2015)...  "Everybody is affected by cancer sooner or later," ... brutal. We,ve got to get away from that."  If ... a loved one or friend battling for their life ... and other treatments cause the human body. It,s almost ... and succumb to the disease. Dr. Dionne has developed ...
(Date:4/20/2015)... 20, 2015 /CNW/ - Portage Biotech Inc. ("Portage" or ... is pleased to announce that its wholly owned subsidiary, ... study that showed one of its proprietary human-derived CPP ... tissue through inhibition of NFkB signalling even if administered ... permeability of the blood brain barrier (BBB) in mice ...
(Date:4/20/2015)... , April 20, 2015   Meditope Biosciences, ... using its proprietary technology, today announced presentation of data ... the development of antibody-drug conjugates (ADCs). The data were presented ... taking place April 18-22 in Philadelphia ... these data which point to the many commercial applications ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2
... May 17, 2011 Amgen (NASDAQ: AMGN ... 3 trial (,147) demonstrating that XGEVA™ (denosumab) significantly increased ... men with castrate-resistant metastatic prostate cancer that has not ... study were presented for the first time today in ...
... DIEGO, May 17, 2011 P ... that it has submitted a Biologics Master File (BMF) to ... grade CRM197 carrier protein to support the development of conjugate ... Proteins is supplying cGMP grade CRM197 carrier protein to multiple ...
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company successfully showcased ... ("the fair") recently held in Chengdu, China. ...
Cached Biology Technology:Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 2Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 3Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 4Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 5Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 6Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 7Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 8Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 9Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... the worlds of law, geography, economics, public health ... College London) on Friday September 19th to examine ... locally-rooted champions for global sustainability, reaching out to ... change. The symposium, which is called: "The Sustainable ...
... no such thing as a ,safe, tan based on ultraviolet ... the October issue of Pigment Cell & Melanoma Research ... Cell Societies (IFPCS) and the Society for Melanoma Research. ... in the fields of cell biology, dermatology and epidemiology ...
... the U.S. Environmental Protection Agency (EPA) have made ... Implications of Nanotechnology (CEIN). The centers, led ... nanomaterials interact with the environment and with living ... assessment and mitigation strategies useful in the development ...
Cached Biology News:Universities develop a more sustainable future 2More than skin deep: There's no such thing as a 'safe' suntan, researchers warn 2NSF and EPA establish 2 centers for environmental implications of nanotechnology 2NSF and EPA establish 2 centers for environmental implications of nanotechnology 3NSF and EPA establish 2 centers for environmental implications of nanotechnology 4
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: